IS6209A - Ný blanda - Google Patents

Ný blanda

Info

Publication number: IS6209A
Authority: IS; Iceland
Prior art keywords: omeprazole; dosage form; core material; alkaline; new mix
Prior art date: 1999-06-22

Application number

IS6209A

Other languages

English (en)

Inventor

Johan Lundberg Per

Sjöblom Brita

Original Assignee

Astrazeneca Ab

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-06-22

Filing date

2001-12-21

Publication date

2001-12-21

2001-12-21 Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab

2001-12-21 Publication of IS6209A publication Critical patent/IS6209A/is

Links

239000011162 core material Substances 0.000 abstract 2
159000000011 group IA salts Chemical class 0.000 abstract 2
229960000381 omeprazole Drugs 0.000 abstract 2
SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 abstract 1
239000004480 active ingredient Substances 0.000 abstract 1
239000000654 additive Substances 0.000 abstract 1
239000003795 chemical substances by application Substances 0.000 abstract 1
239000002552 dosage form Substances 0.000 abstract 1
239000012528 membrane Substances 0.000 abstract 1
239000006186 oral dosage form Substances 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 abstract 1
230000008961 swelling Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5005—Wall or coating material
- A61K9/5021—Organic macromolecular compounds
- A61K9/5036—Polysaccharides, e.g. gums, alginate; Cyclodextrin
- A61K9/5042—Cellulose; Cellulose derivatives, e.g. phthalate or acetate succinate esters of hydroxypropyl methylcellulose
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Plural Heterocyclic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Compositions Of Macromolecular Compounds (AREA)

IS6209A 1999-06-22 2001-12-21 Ný blanda IS6209A (is)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
SE9902386A SE9902386D0 (sv)	1999-06-22	1999-06-22	New formulation
PCT/SE2000/001310 WO2000078293A1 (en)	1999-06-22	2000-06-20	New formulation

Publications (1)

Publication Number	Publication Date
IS6209A true IS6209A (is)	2001-12-21

Family

ID=20416209

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IS6209A IS6209A (is)	1999-06-22	2001-12-21	Ný blanda

Country Status (29)

Country	Link
EP (1)	EP1191926B1 (is)
JP (1)	JP2003502359A (is)
KR (1)	KR100717661B1 (is)
CN (1)	CN1243547C (is)
AT (1)	ATE291901T1 (is)
AU (1)	AU778158B2 (is)
BR (1)	BR0011894A (is)
CA (1)	CA2376226C (is)
CZ (1)	CZ20014579A3 (is)
DE (1)	DE60019116T2 (is)
DK (1)	DK1191926T3 (is)
EE (1)	EE200100693A (is)
ES (1)	ES2235912T3 (is)
HK (1)	HK1044480B (is)
HU (1)	HUP0201489A3 (is)
IL (2)	IL146818A0 (is)
IS (1)	IS6209A (is)
MX (1)	MXPA01012636A (is)
NO (1)	NO20016346L (is)
NZ (1)	NZ516186A (is)
PL (1)	PL352873A1 (is)
PT (1)	PT1191926E (is)
RU (1)	RU2240110C2 (is)
SE (1)	SE9902386D0 (is)
SK (1)	SK285326B6 (is)
TR (1)	TR200103693T2 (is)
UA (1)	UA73302C2 (is)
WO (1)	WO2000078293A1 (is)
ZA (1)	ZA200109803B (is)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5840737A (en)	1996-01-04	1998-11-24	The Curators Of The University Of Missouri	Omeprazole solution and method for using same
US6489346B1 (en)	1996-01-04	2002-12-03	The Curators Of The University Of Missouri	Substituted benzimidazole dosage forms and method of using same
US8206741B2 (en)	2001-06-01	2012-06-26	Pozen Inc.	Pharmaceutical compositions for the coordinated delivery of NSAIDs
MXPA04009968A (es)	2002-04-09	2004-12-13	Flamel Tech Sa	Formulacion farmaceutica oral bajo forma de suspension acuosa de microcapsulas que permiten la liberacion modificada de principio (s) activo (s).
SI21402A (sl)	2003-02-12	2004-08-31	LEK farmacevtska dru�ba d.d.	Obloženi delci in farmacevtske oblike
CA2517289A1 (en) *	2003-02-28	2004-09-10	Ranbaxy Laboratories Limited	Stable pharmaceutical composition of rabeprazole and processes for their preparation
US8993599B2 (en)	2003-07-18	2015-03-31	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
WO2005027876A1 (en) *	2003-08-28	2005-03-31	Ranbaxy Laboratories Limited	Pharmaceutical compositions of benzimidazole and processes for their preparation
JP2007504261A (ja) *	2003-09-03	2007-03-01	エイジーアイ・セラピューティクス・リサーチ・リミテッド	プロトンポンプ阻害剤製剤、並びに当該製剤を製造及び使用する方法関連出願の表示
US8165651B2 (en)	2004-02-09	2012-04-24	Abbott Diabetes Care Inc.	Analyte sensor, and associated system and method employing a catalytic agent
US7699964B2 (en)	2004-02-09	2010-04-20	Abbott Diabetes Care Inc.	Membrane suitable for use in an analyte sensor, analyte sensor, and associated method
US8906940B2 (en)	2004-05-25	2014-12-09	Santarus, Inc.	Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20080214618A1 (en) *	2004-08-23	2008-09-04	Auckland Uniservices Limited	Gastric Therapies Amd Compositions Therefor
US7803817B2 (en) *	2005-05-11	2010-09-28	Vecta, Ltd.	Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en)	2005-05-11	2011-07-19	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion
FR2885526B1 (fr) *	2005-05-13	2007-07-27	Flamel Technologies Sa	Medicament oral a base d'inhibiteur de pompe a protons
RU2408368C2 (ru)	2005-06-27	2011-01-10	Биовэйл Лэборэториз Интернэшнл С.Р.Л.	Препараты соли бупропиона с модифицированным высвобождением
WO2007074909A1 (ja) *	2005-12-28	2007-07-05	Takeda Pharmaceutical Company Limited	放出制御固形製剤
US7885698B2 (en)	2006-02-28	2011-02-08	Abbott Diabetes Care Inc.	Method and system for providing continuous calibration of implantable analyte sensors
US9233092B2 (en)	2006-07-25	2016-01-12	Vecta, Ltd.	Compositions and methods for inhibiting gastric acid secretion using derivatives of small dicarboxylic acids in combination with PPI
WO2008044236A2 (en) *	2006-10-10	2008-04-17	Dexcel Pharma Technologies Ltd.	Improved release of statins in the intestine
EA201100313A1 (ru)	2008-09-09	2011-10-31	Астразенека Аб	Способ доставки фармацевтической композиции пациенту, нуждающемуся в этом
CA2764963C (en)	2009-06-25	2016-11-01	Astrazeneca Ab	Method for treating a patient at risk for developing an nsaid-associated ulcer
PH12013502325A1 (en)	2011-05-13	2014-02-10	Eb Ip Hybritabs B V	Drug delivery system
EP2586429A1 (en) *	2011-10-26	2013-05-01	Freund Pharmatec Ltd.	Multi-unit drug delivery device for pulsatile or sustained release
BR112014016085A8 (pt)	2011-12-28	2017-07-04	Pozen Inc	composições aprimoradas e métodos para distribuição de omeprazol mais ácido acetilsalicílico
WO2013122554A1 (en)	2012-02-14	2013-08-22	Mahmut Bilgic	Pellet formulations comprising esomeprazole
CN103127026B (zh) *	2013-02-05	2017-02-15	悦康药业集团有限公司	一种奥美拉唑肠溶胶囊及其制备方法
RU2683203C2 (ru)	2013-12-31	2019-03-26	Эбботт Дайабитиз Кэр Инк.	Снабженный автономным питанием датчик аналита и использующие его устройства
US20170042806A1 (en)	2015-04-29	2017-02-16	Dexcel Pharma Technologies Ltd.	Orally disintegrating compositions
RU2614730C1 (ru) *	2016-02-05	2017-03-28	Игорь Юрьевич Чичерин	Антибактериальное средство и способ лечения кишечного иерсиниоза, или псевдотуберкулеза, или эшерихиоза
US10736855B2 (en) *	2016-02-25	2020-08-11	Dexcel Pharma Technologies Ltd.	Compositions comprising proton pump inhibitors
JP6426115B2 (ja) *	2016-04-06	2018-11-21	ニプロ株式会社	カルシウムブロッカーを含有する固形医薬組成物
JP6462625B2 (ja) *	2016-04-06	2019-01-30	ニプロ株式会社	カルシウムブロッカーを含有する錠剤
US10076494B2 (en)	2016-06-16	2018-09-18	Dexcel Pharma Technologies Ltd.	Stable orally disintegrating pharmaceutical compositions
CN109125282B (zh) *	2018-09-05	2020-07-14	珠海润都制药股份有限公司	一种奥美拉唑肠溶胶囊及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA1327010C (en) *	1986-02-13	1994-02-15	Tadashi Makino	Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) *	1986-04-30	1987-11-04	Haessle Ab	Coated omeprazole tablets
YU48263B (sh) *	1991-06-17	1997-09-30	Byk Gulden Lomberg Chemische Fabrik Gmbh.	Postupak za dobijanje farmaceutskog preparata na bazi pantoprazola
SE9302395D0 (sv) *	1993-07-09	1993-07-09	Ab Astra	New pharmaceutical formulation
US5840332A (en) *	1996-01-18	1998-11-24	Perio Products Ltd.	Gastrointestinal drug delivery system
ZA979937B (en) *	1996-11-06	1999-05-18	Sharmatek Inc	Delayed delivery system for acid-sensitive drugs
SE9702000D0 (sv) *	1997-05-28	1997-05-28	Astra Ab	New pharmaceutical formulation
ATE303809T1 (de) *	1997-12-08	2005-09-15	Altana Pharma Ag	Orale verabreichungsform enthaltend einen protonenpumpeninhbitor (z.b. pantoprazole)
WO2000009092A1 (en) *	1998-08-12	2000-02-24	Byk Gulden Lomberg Chemische Fabrik Gmbh	Oral administration form for pyridin-2-ylmethylsulfinyl-1h-benzimidazoles

1999
- 1999-06-22 SE SE9902386A patent/SE9902386D0/xx unknown
2000
- 2000-06-20 RU RU2001132861/15A patent/RU2240110C2/ru not_active IP Right Cessation
- 2000-06-20 UA UA2001128420A patent/UA73302C2/uk unknown
- 2000-06-20 HK HK02106171.6A patent/HK1044480B/en not_active IP Right Cessation
- 2000-06-20 DK DK00946614T patent/DK1191926T3/da active
- 2000-06-20 SK SK1825-2001A patent/SK285326B6/sk not_active IP Right Cessation
- 2000-06-20 NZ NZ516186A patent/NZ516186A/en unknown
- 2000-06-20 CZ CZ20014579A patent/CZ20014579A3/cs unknown
- 2000-06-20 DE DE60019116T patent/DE60019116T2/de not_active Expired - Lifetime
- 2000-06-20 TR TR2001/03693T patent/TR200103693T2/xx unknown
- 2000-06-20 EP EP00946614A patent/EP1191926B1/en not_active Expired - Lifetime
- 2000-06-20 PL PL00352873A patent/PL352873A1/xx unknown
- 2000-06-20 AT AT00946614T patent/ATE291901T1/de not_active IP Right Cessation
- 2000-06-20 KR KR1020017016442A patent/KR100717661B1/ko not_active Expired - Fee Related
- 2000-06-20 CN CNB008093369A patent/CN1243547C/zh not_active Expired - Fee Related
- 2000-06-20 HU HU0201489A patent/HUP0201489A3/hu unknown
- 2000-06-20 BR BR0011894-0A patent/BR0011894A/pt not_active Application Discontinuation
- 2000-06-20 PT PT00946614T patent/PT1191926E/pt unknown
- 2000-06-20 WO PCT/SE2000/001310 patent/WO2000078293A1/en not_active Ceased
- 2000-06-20 JP JP2001504358A patent/JP2003502359A/ja active Pending
- 2000-06-20 EE EEP200100693A patent/EE200100693A/xx unknown
- 2000-06-20 CA CA002376226A patent/CA2376226C/en not_active Expired - Fee Related
- 2000-06-20 AU AU60344/00A patent/AU778158B2/en not_active Ceased
- 2000-06-20 ES ES00946614T patent/ES2235912T3/es not_active Expired - Lifetime
- 2000-06-20 MX MXPA01012636A patent/MXPA01012636A/es active IP Right Grant
- 2000-06-20 IL IL14681800A patent/IL146818A0/xx active IP Right Grant
2001
- 2001-11-28 ZA ZA200109803A patent/ZA200109803B/en unknown
- 2001-11-29 IL IL146818A patent/IL146818A/en not_active IP Right Cessation
- 2001-12-21 NO NO20016346A patent/NO20016346L/no not_active Application Discontinuation
- 2001-12-21 IS IS6209A patent/IS6209A/is unknown

Also Published As

Publication number	Publication date
HUP0201489A3 (en)	2004-05-28
DK1191926T3 (da)	2005-06-13
ATE291901T1 (de)	2005-04-15
DE60019116T2 (de)	2006-02-09
CA2376226C (en)	2009-10-20
MXPA01012636A (es)	2002-06-21
UA73302C2 (en)	2005-07-15
KR20020012002A (ko)	2002-02-09
CN1243547C (zh)	2006-03-01
NZ516186A (en)	2003-11-28
AU778158B2 (en)	2004-11-18
HK1044480B (en)	2005-08-26
TR200103693T2 (tr)	2002-05-21
DE60019116D1 (de)	2005-05-04
SK285326B6 (sk)	2006-11-03
NO20016346L (no)	2002-02-18
BR0011894A (pt)	2002-04-02
KR100717661B1 (ko)	2007-05-14
CN1356893A (zh)	2002-07-03
ES2235912T3 (es)	2005-07-16
CZ20014579A3 (cs)	2002-05-15
CA2376226A1 (en)	2000-12-28
HUP0201489A2 (hu)	2002-11-28
HK1044480A1 (en)	2002-10-25
PT1191926E (pt)	2005-07-29
EP1191926A1 (en)	2002-04-03
ZA200109803B (en)	2003-02-28
IL146818A0 (en)	2002-07-25
PL352873A1 (en)	2003-09-08
NO20016346D0 (no)	2001-12-21
SE9902386D0 (sv)	1999-06-22
AU6034400A (en)	2001-01-09
RU2240110C2 (ru)	2004-11-20
EP1191926B1 (en)	2005-03-30
JP2003502359A (ja)	2003-01-21
IL146818A (en)	2007-10-31
WO2000078293A1 (en)	2000-12-28
EE200100693A (et)	2003-02-17
SK18252001A3 (sk)	2002-09-10

Publication	Publication Date	Title
SE9902386D0 (sv)	1999-06-22	New formulation
EE05383B1 (et)	2011-02-15	Polarlkarboksamiidhendid,ÁnendeÁvalmistamineÁjaÁkasutamineÁlipiiditasetÁalandavateÁtoimeainetenaÁningÁneidÁsisaldavÁfarmatseutilineÁkompositsioon
NO20012222L (no)	2001-07-02	Farmasöytisk formulering innbefattende omeprazol
AP2001002237A0 (en)	2001-09-30	Hydrogel-driven drug dosage form.
MY129356A (en)	2007-03-30	Electrospun pharmaceutical compositions
EE04800B1 (et)	2007-04-16	Oraalne manustamisvorm happes ebapüsiva toimeainetarbeks, toimeaineühik, selle valmistamismeetod ja kasutamine ning meetod oraalse manustamisvormi valmistamiseks
PL357944A1 (en)	2004-08-09	Intradermal-penetration agents for topical local anesthetic administration
MY101593A (en)	1991-12-17	Sustained release preparation.
SE9702000D0 (sv)	1997-05-28	New pharmaceutical formulation
IS4146A (is)	1994-10-31	Lyfjablanda til að gefa dýrum um munn sem inniheldur prótonupumpublokkara
TWI235068B (en)	2005-07-01	Sustained-release pharmaceutical composition
DK1283700T3 (da)	2006-07-24	Farmaceutiske sustained release-præparater til parenteral administration af biologisk aktive hydrofile forbindelser
BR0107565A (pt)	2003-02-11	Formas de dosagem de benzimidazol substituìdo e método de emprego das mesmas
TR200001942T2 (tr)	2000-11-21	Opioid agonist/antagonist kombinasyonlar
DK1169024T3 (da)	2006-05-08	Prægelatineret stivelse i en formulering med kontrolleret frigivelse
AU2001296865A1 (en)	2002-03-22	(5-(2-hydroxy-4-chlorobenzoyl) aminovaleric acid and salts thereof and compositions containing the same for delivering active agents
FI861923A7 (fi)	1986-11-10	Suulakepuristettavien mikropartikkeleidenvalmistuksessa käytettäviä koostumuksia, jotka aiheuttavat biologisestaktiivisen aineen pitkittyneen vapautumisen, ja näin saadut mikropartikkelit.
HUP0203312A3 (en)	2003-02-28	Pharmaceutically active sulfonamide derivatives, process for their preparation, and pharmaceutical compositions and their use
HU229443B1 (en)	2013-12-30	Betha-carboline particulate form, pharmaceutical compositions containing it, their preparations and their use
DE50005529D1 (de)	2004-04-08	Orale darreichungsformen zur verabreichung einer fixen kombination von tramadol und diclofenac
ID28510A (id)	2001-05-31	Formulasi oral yang baru untuk agonis atau antagonis 5-ht4
ATE254851T1 (de)	2003-12-15	Iod-herstellungszusammensetzung
HRP20050342B1 (hr)	2013-11-08	Farmaceutska formulacija olanzapina
SE9604752D0 (sv)	1996-12-20	Formulation and use
NO20001846D0 (no)	2000-04-10	Nye farmasøytisk aktive forbindelser, deres fremstilling og anvendelse som ECE-inhibitorer